Clinical Trials Sponsored by MorphoSys AG

Total 2332 results

MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
MorphoSys AG

Completed

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Multiple Sclerosis

Germany, Poland, United Kingdom
MorphoSys AG

Active, not recruiting

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND)

Diffuse Large B-cell Lymphoma

Germany, France, Hungary, Italy, Spain, United States, Austria, Czechia, Australia, Israel, Korea, Republic of, Turkey, Taiwan, Argentina, Canada, Colombia, Ireland, Japan, Malaysia, New Zealand, Philippines, Poland, Romania, Russian... and more
MorphoSys AG

Completed

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Diffuse Large B-cell Lymphoma

Belgium, Germany, United States, Austria, Czechia, France, Italy, Portugal, Spain
MorphoSys AG

Terminated

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Acute Lymphoblastic Leukemia

United States
MorphoSys AG

Active, not recruiting

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway)

Diffuse Large B Cell Lymphoma

Spain, Czechia, Korea, Republic of, Israel, Poland, Italy, Austria, France, United States
MorphoSys AG

Completed

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)

Diffuse Large B-cell Lymphoma

Spain, United States, United Kingdom, Italy, Poland, Belgium, Germany, Czechia, France, Hungary
MorphoSys AG

Completed

Lenalidomide Monotherapy in R/R DLBCL (RE-MIND)

Diffuse Large B Cell Lymphoma

France, Italy, United States, Spain
MorphoSys AG

Completed

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Austria, Germany
MorphoSys AG

Completed

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL (RE-MIND2)

Diffuse Large B Cell Lymphoma

France, Italy, Spain, United States, Austria, Australia, Germany, Korea, Republic of, Canada, Denmark, Taiwan, United Kingdom
MorphoSys AG

Completed

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Germany, Netherlands, Poland, Ukraine
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Pfizer
Incyte Corporation; MorphoSys AG

Recruiting

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

United States, Japan, Puerto Rico, Korea, Republic of
MorphoSys AG
Iqvia Pty Ltd

Recruiting

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND)

Diffuse Large B-cell Lymphoma

United States
MorphoSys AG
ICON Clinical Research

Active, not recruiting

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)

Diffuse Large B-cell Lymphoma

United States, Hungary, Italy, Poland, Spain, Czechia, Germany, Australia, Austria, Canada, Croatia, Finland, France, Israel, Korea, Republic of, New Zealand, Portugal, Romania, Serbia, Singapore, Taiwan, Turkey, United Kingdom
Bayer
ImmunoGen, Inc.; MorphoSys AG

Completed

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)

Neoplasms

United States, Spain, United Kingdom, Korea, Republic of, Canada, France, Belgium, Australia, Singapore, Italy, Netherlands, Switzerland
MorphoSys AG
Clinigen Healthcare Ltd

Approved for marketing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

DLBCL
Mario Negri Institute for Pharmacological Research
MorphoSys AG

Active, not recruiting

MOR202 for Refractory MN (MONET)

Membranous Nephropathy

Italy
Ohio State University Comprehensive Cancer Center
MorphoSys AG

Active, not recruiting

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic... and other conditions

United States
Alvaro Alencar, MD
Incyte Corporation; BeiGene; MorphoSys AG

Recruiting

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma (ZANU-TAFA)

Mantle Cell Lymphoma

United States
Bayer
ImmunoGen and MorphoSys

Completed

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Mesothelioma

Belgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
Lan Coffman
National Cancer Institute (NCI); MorphoSys AG

Recruiting

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

United States
Bottneuro AG
Hemex AG

Active, not recruiting

Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants (MindStim)

Healthy Participants | Healthy Population

Switzerland
Santersus AG
ISS AG

Not yet recruiting

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating cfDNA/NETs in Subjects With Sepsis (NUC-CAP)

Sepsis | Respiratory Failure

United Kingdom, Germany, Switzerland
SynDermix AG
ISS AG

Withdrawn

Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (SDX-3101)

Chronic Rhinosinusitis Without Nasal Polyps

Germany, Austria, Switzerland
Tetec AG
Aesculap AG

Completed

Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects (HIP-ACTION)

Cartilage Disease

Germany
Tetec AG
Aesculap AG

Completed

Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects (NISANIK)

Cartilage Diseases

Germany
iOMEDICO AG
Roche Pharma AG

Active, not recruiting

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion (REALTRK)

NTRK Family Gene Mutation

Switzerland, Germany
iOMEDICO AG
Roche Pharma AG

Completed

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (CHAPLIN)

Extensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Germany
Spiden AG
DCB Research AG

Completed

A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults With Type-1 Diabetes Mellitus

Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With Hyperglycemia

Switzerland
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; MorphoSys AG; Swim Across America; Daniel...

Recruiting

Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome

United States
Swiss Medical Food AG
iOMEDICO AG

Completed

Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy (STEFANO)

CIPN in Adjuvant Colon Cancer Patients | CIPN in Adjuvant Breast Cancer Patients

Germany
hemotune AG

Not yet recruiting

First in Human Trial to Assess the Safety & Efficacy of HemoSystem REBOOT in Patients With Sepsis-induced Immunosuppression ((RESTORE))

Septic Shock

Switzerland
ARTIDIS AG

Recruiting

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions (ANGEL)

Breast Cancer

United States
Medicel AG

Not yet recruiting

Evaluation of Performance of New IFIS Sleeve

Cataract
Lumendo AG

Recruiting

A Study to Compare Various Root Canal Cleaning Devices Based on Cavitation,Ultrasonic and Conventional Methods.

Apical Periodontitis

Turkey
Aesculap AG

Not yet recruiting

Comparative Study of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty (ORMAK)

Joint Diseases | Osteoarthritis, Knee | Rheumatoid Arthritis of Knee | Posttraumatic Arthropathy

Germany
Pregnolia AG

Recruiting

Mapping the Uterine Cervix Stiffness of Pregnant Women at Mid Gestation (MAPVIX)

Cervix; Pregnancy

Switzerland
Stratpharma AG

Recruiting

StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis

Radiation Dermatitis

United States
Aesculap AG

Recruiting

Ceramic Modular Dual Mobility in Primary Total Hip Arthroplasty (THA) (CeMoD-prime)

Coxarthrosis; Primary

Czechia
Biotronik AG
Biotronik AG

Not yet recruiting

Safety and Clinical Performance of the DREAMS 3G Resorbable Magnesium Scaffold System (BIOMAG-II)

Myocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Ischemic Heart Disease | Atherosclerosis, Coronary
Gaia AG

Recruiting

Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus (OnSeT-2D)

Type 2 Diabetes

Germany
Carag AG

Not yet recruiting

Sensing Oxygen Saturations Using Abdominal NIRS With an Investigational Realtime Device (Songbird) ((Songbird))

NEC
Lindenhofgruppe AG

Recruiting

Comparison of Standalone Anterior Lumbar Interbody Fusion (ALIF) L5/S1 Performed With Either rhBMP-2 or ViviGen®

Degenerative Disc Disease | Spondylosis | Spondylolisthesis

Switzerland
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
Biotronik AG

Recruiting

Resorbable Magnesium Scaffolds Registry

Coronary Artery Disease

Germany
iOMEDICO AG

Recruiting

Breast Cancer Registry Platform (OPAL)

Breast Cancer

Germany
VectivBio AG

Completed

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF (STARS)

Short Bowel Syndrome

United States, France, United Kingdom, Israel, Korea, Republic of, Germany, Japan, Taiwan, Sweden, Belgium, Spain, Czechia, Hungary, Norway, Italy, Argentina, Denmark, Poland
Immunic AG

Active, not recruiting

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multiple Sclerosis

United States, Germany, Netherlands, Bulgaria, Serbia, Canada, Czechia, Moldova, Republic of, North Macedonia, Poland, Romania, Ukraine

Clinical Trials Sponsored by MorphoSys AG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations